Transperineal Ultrasound as a Biofeedback Tool for Pelvic Floor Muscle Therapy in Postpartum Patients
Launched by SINGAPORE GENERAL HOSPITAL · Jul 3, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a special ultrasound scan called transperineal ultrasound can help new mothers do pelvic floor muscle exercises more effectively after giving birth. These exercises are important because they strengthen the muscles that support the bladder, uterus, and bowel, helping to prevent issues like leaks or discomfort after delivery. Usually, a physiotherapist guides women through these exercises, but it can be hard to know if the exercises are done correctly. This study is testing if the ultrasound, which shows real-time images of the pelvic muscles, can give both the patient and the therapist visual feedback to improve the exercise technique.
Women who are eligible for this study are between 21 and 45 years old, have recently had a vaginal birth of one baby (within the last 4 months), and are not currently pregnant. Women who have had a cesarean section, pelvic surgery, or certain neurological conditions are not eligible. Participants will attend sessions where the ultrasound is used while they do their pelvic floor exercises, allowing them and the therapist to see how well the muscles are working. This trial aims to find out if this tool can make pelvic floor therapy more effective and easier to follow, helping new moms protect their pelvic health after childbirth.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female participants
- • Aged 21 - 45 years old.
- • Within 4 months of a singleton, vaginal delivery
- Exclusion Criteria:
- • Currently pregnant
- • Over 4 months since vaginal birth.
- • Previous caesarean delivery.
- • Previous pelvic floor surgery (eg. pelvic floor repair, continence surgery, cervicetomy,cosmetic pelvic floor procedures)
- • Neurological disorder affecting muscle contraction (eg. Guillan-Barre syndrome, motorneuron disease, multiple sclerosis)
About Singapore General Hospital
Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported